{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1"},{"groupId":"OG001","value":"44.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2286"},{"groupId":"OG001","value":"2310"}],"units":"Participants"}],"title":"Baseline: Not anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.4"},{"groupId":"OG001","value":"50.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2286"},{"groupId":"OG001","value":"2310"}],"units":"Participants"}],"title":"Baseline: Moderate anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5"},{"groupId":"OG001","value":"5.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2286"},{"groupId":"OG001","value":"2310"}],"units":"Participants"}],"title":"Baseline: Extreme anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6"},{"groupId":"OG001","value":"52.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2076"},{"groupId":"OG001","value":"2125"}],"units":"Participants"}],"title":"Week 13: Not anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4"},{"groupId":"OG001","value":"44.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2076"},{"groupId":"OG001","value":"2125"}],"units":"Participants"}],"title":"Week 13: Moderate anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0"},{"groupId":"OG001","value":"3.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2076"},{"groupId":"OG001","value":"2125"}],"units":"Participants"}],"title":"Week 13: Extreme anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5"},{"groupId":"OG001","value":"55.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2060"},{"groupId":"OG001","value":"2075"}],"units":"Participants"}],"title":"Week 25: No anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.9"},{"groupId":"OG001","value":"41.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2060"},{"groupId":"OG001","value":"2075"}],"units":"Participants"}],"title":"Week 25: Moderate anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"2.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2060"},{"groupId":"OG001","value":"2075"}],"units":"Participants"}],"title":"Week 25: Extreme anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.5"},{"groupId":"OG001","value":"58.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2041"},{"groupId":"OG001","value":"2101"}],"units":"Participants"}],"title":"EOT: Not anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9"},{"groupId":"OG001","value":"39.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2041"},{"groupId":"OG001","value":"2101"}],"units":"Participants"}],"title":"EOT: Moderate anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"2.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2041"},{"groupId":"OG001","value":"2101"}],"units":"Participants"}],"title":"EOT: Extreme anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4"},{"groupId":"OG001","value":"59.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1916"},{"groupId":"OG001","value":"1915"}],"units":"Participants"}],"title":"FU Month 18: Not anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.2"},{"groupId":"OG001","value":"37.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1916"},{"groupId":"OG001","value":"1915"}],"units":"Participants"}],"title":"FU Month 18: Moderate anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4"},{"groupId":"OG001","value":"3.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1916"},{"groupId":"OG001","value":"1915"}],"units":"Participants"}],"title":"FU Month 18: Extreme anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.8"},{"groupId":"OG001","value":"61.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1860"},{"groupId":"OG001","value":"1872"}],"units":"Participants"}],"title":"FU Month 24: Not anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8"},{"groupId":"OG001","value":"36.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1860"},{"groupId":"OG001","value":"1872"}],"units":"Participants"}],"title":"FU Month 24: Moderate anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4"},{"groupId":"OG001","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1860"},{"groupId":"OG001","value":"1872"}],"units":"Participants"}],"title":"FU Month 24: Extreme anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.0"},{"groupId":"OG001","value":"61.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1815"},{"groupId":"OG001","value":"1787"}],"units":"Participants"}],"title":"FU Month 36: Not anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"35.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1815"},{"groupId":"OG001","value":"1787"}],"units":"Participants"}],"title":"FU Month 36: Moderate anxious/depress"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1815"},{"groupId":"OG001","value":"1787"}],"units":"Participants"}],"title":"FU Month 36: Extreme anxious/depress"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2400"},{"groupId":"OG001","value":"2404"}],"units":"Participants"}],"description":"EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \\[scored as 1\\], some or moderate problems \\[scored as 2\\], and extreme problems \\[scored as 3\\]). Percentage of participants with each of the following responses in anxiety/depression domain was reported: I am not anxious or depressed; I am moderately anxious or depressed; and I am extremely anxious or depressed. Response percentages may not add up to 100% due to data rounding.","groups":[{"description":"Participants received pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).","id":"OG000","title":"Pertuzumab + Trastuzumab + Chemotherapy"},{"description":"Participants received placebo matched to pertuzumab IV Q3W and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin AUC 6 (up to 900 mg).","id":"OG001","title":"Placebo + Trastuzumab + Chemotherapy"}],"paramType":"NUMBER","populationDescription":"ITT population. Number analyzed=participants evaluable for this outcome measure at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36","title":"Percentage of Participants With Response for EQ-5D-3L Questionnaire: Anxiety/Depression Domain","type":"SECONDARY","unitOfMeasure":"percentage of participants"}